This Annual Report covers NIIMBL’s accomplishments from March 1, 2021 to February 28, 2022.
The NIIMBL mission is to accelerate biopharmaceutical manufacturing innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
NIIMBL will lead and transform the development and adoption of next-generation biopharmaceutical manufacturing technologies that contribute to patient well-being. As a public–private partnership, NIIMBL will forge and catalyze advancements that are vital to the acceleration of innovative technologies and a skilled workforce, and these strategic efforts and investments will be undertaken to secure U.S. biopharmaceutical manufacturing leadership.